Biopharmaceutical company MapLight Therapeutics applies for a U.S. IPO aiming to raise up to $100 million
I'm PortAI, I can summarize articles.
Biotechnology company MapLight Therapeutics submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) last Friday, planning to raise up to $100 million. The company focuses on therapies for neuropsychiatric disorders and central nervous system diseases, with its core candidate drug ML-007C-MA currently undergoing two Phase 2 clinical trials. MapLight plans to list on NASDAQ under the ticker symbol MPLT, with joint lead underwriters including Morgan Stanley
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments